FOXO TECHNOLOGIES INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
FOXO TECHNOLOGIES INC. (FOXO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -8.50% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2025-04-15
- FOXO TECHNOLOGIES INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -8.50%.
- FOXO TECHNOLOGIES INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -4.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2024-12-31 | -8.50% 10-K · filed 2025-04-15 |
| 2023-12-31 | -4.40% 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |